Medpace Holdings, Inc. $MEDP Shares Acquired by Capital Impact Advisors LLC

Capital Impact Advisors LLC lifted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 31.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,995 shares of the company’s stock after acquiring an additional 6,495 shares during the period. Medpace accounts for about 3.1% of Capital Impact Advisors LLC’s holdings, making the stock its 15th biggest position. Capital Impact Advisors LLC’s holdings in Medpace were worth $13,880,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Clarkston Capital Partners LLC purchased a new position in Medpace during the 2nd quarter worth $40,569,000. Cibc World Market Inc. purchased a new stake in shares of Medpace in the third quarter valued at about $5,033,000. Brighton Jones LLC boosted its stake in shares of Medpace by 160.4% during the third quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock worth $2,087,000 after buying an additional 2,501 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Medpace by 150.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 15,193 shares of the company’s stock worth $8,080,000 after buying an additional 9,117 shares during the period. Finally, Baillie Gifford & Co. grew its holdings in shares of Medpace by 12.0% during the third quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after buying an additional 62,503 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Up 1.5%

NASDAQ MEDP opened at $450.41 on Friday. The stock has a market capitalization of $12.78 billion, a P/E ratio of 29.44, a P/E/G ratio of 2.16 and a beta of 1.44. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $628.92. The firm has a 50-day moving average price of $523.62 and a 200 day moving average price of $538.95.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. During the same quarter in the previous year, the company earned $3.67 EPS. The firm’s revenue for the quarter was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MEDP. Barclays upgraded Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 price target on the stock in a research report on Friday, March 6th. Truist Financial decreased their price objective on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research report on Wednesday, February 11th. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price on the stock in a research note on Friday, February 13th. Robert W. Baird raised Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 target price on the stock in a report on Tuesday, February 10th. Finally, BMO Capital Markets restated a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th. Five equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $486.67.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.